Marijuana legalization is coming to the United States.
Just recently, New York lawmakers moved to legalize cannabis in their state. That came after other states like California and Colorado legalized recreational cannabis use. With two of the most influential States having legalized cannabis, it seems like only a matter of time until Joe Biden pursues federal-level decriminalization.
This is a significant development. And Canadian pot firm Aphria (TSX:APHA)(NASDAQ:APHA) stands to gain from it. Thanks to its upcoming merger with Tilray (NASDAQ:TLRY), Aphria will have a substantial physical presence in the United States. That may give it an advantage when selling in that market. In this article, I’ll explore how much money Aphria/Tilray could make from U.S. weed legalization.
How much Aphria/Tilray could make from the merger
According to New Frontier, the U.S. legal marijuana industry was worth $13.6 billion in 2019. The more states legalize cannabis, the higher that figure is likely to go.
Currently, there are a number of companies supplying recreational and medical marijuana to the United States. That includes both Canadian firms and home-grown U.S. operations like Tilray. If the new Aphria/Tilray company were able to grab 20% of the U.S. marijuana industry, based on 2019 sales numbers, it would generate $2.72 billion in revenue.
Of course, total legal marijuana sales are likely to be higher in the future, and 20% is just an estimate. But even figuring fairly conservatively, we can see that there is significant potential revenue to be gained here. Tilray is probably already getting a nice share of the U.S. marijuana revenue just mentioned. Once the Aphria/Tilray merger closes, APHA investors will get a chunk of it as well. So, for Canadian investors holding APHA stock but not TLRY stock, this is “new” revenue.
How much will current Aphria investors get?
The biggest positive of the Aphria/Tilray merger for Aphria investors is that Aphria is getting the better end of the deal. Aphria shareholders will get 68% of the newly formed company. Therefore, the deal will increase Aphria’s stock value. Based on the value of the Tilray shares Aphria is to receive, APHA technically traded at a discount briefly this year. This made it one of the easiest arbitrage opportunities in recent stock market history, though APHA’s stock price has since closed the gap.
In recent years, there hasn’t been a whole lot of interest in cannabis stocks. After Canadian legalization underwhelmed investors, the cannabis industry went dormant — at least in the media. That’s beginning to change. With U.S. legalization looming and the sector’s biggest-ever merger set to close, we could see another speculative rally in cannabis stocks. Or, at least, more media coverage.
As of right now, it’s unclear whether Joe Biden will move to decriminalize marijuana in the United States. But it’s abundantly clear that more and more states are already moving in that direction. As this trend develops, Aphria/Tilray will likely get a lot of the new revenue generated. That’s a boon for Aphria shareholders, who will own the lion’s share of the newly formed company.
Speaking of great stocks...
Motley Fool Canada's market-beating team has just released a brand-new FREE report revealing 5 "dirt cheap" stocks that you can buy today for under $49 a share.
Our team thinks these 5 stocks are critically undervalued, but more importantly, could potentially make Canadian investors who act quickly a fortune.
Don't miss out! Simply click the link below to grab your free copy and discover all 5 of these stocks now.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.
Fool contributor Andrew Button has no position in any of the stocks mentioned.